ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis
USA - NASDAQ:RARE - US90400D1081 - Common Stock
33.02 USD
-0.51 (-1.52%)
RARE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. RARE may be in some trouble as it scores bad on both profitability and health. RARE shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
RARE had negative earnings in the past year.
In the past year RARE has reported a negative cash flow from operations.
RARE had negative earnings in each of the past 5 years.
RARE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -48.71%, RARE is in line with its industry, outperforming 51.04% of the companies in the same industry.
RARE has a Return On Equity of -6330.70%. This is amonst the worse of the industry: RARE underperforms 83.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.71% | ||
| ROE | -6330.7% | ||
| ROIC | N/A |
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RARE has a better Gross Margin (84.69%) than 87.38% of its industry peers.
RARE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RARE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
RARE has more shares outstanding than it did 1 year ago.
RARE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RARE has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.21, we must say that RARE is in the distress zone and has some risk of bankruptcy.
RARE has a Altman-Z score (-4.21) which is in line with its industry peers.
A Debt/Equity ratio of 83.39 is on the high side and indicates that RARE has dependencies on debt financing.
The Debt to Equity ratio of RARE (83.39) is worse than 84.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 83.39 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.21 |
ROIC/WACCN/A
WACC8.26%
2.3 Liquidity
RARE has a Current Ratio of 1.89. This is a normal value and indicates that RARE is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.89, RARE is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
A Quick Ratio of 1.74 indicates that RARE should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.74, RARE is not doing good in the industry: 78.53% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
RARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.19%, which is quite good.
The Revenue has grown by 20.63% in the past year. This is a very strong growth!
RARE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.13% yearly.
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%
3.2 Future
The Earnings Per Share is expected to grow by 25.18% on average over the next years. This is a very strong growth
RARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.44% yearly.
EPS Next Y18.8%
EPS Next 2Y16.29%
EPS Next 3Y23.42%
EPS Next 5Y25.18%
Revenue Next Year20.05%
Revenue Next 2Y21.83%
Revenue Next 3Y29.87%
Revenue Next 5Y32.44%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RARE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RARE's earnings are expected to grow with 23.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.29%
EPS Next 3Y23.42%
5. Dividend
5.1 Amount
RARE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RARE (11/13/2025, 1:06:52 PM)
33.02
-0.51 (-1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.2%
Inst Owner Change-0.92%
Ins Owners3.49%
Ins Owner Change1.33%
Market Cap3.18B
Revenue(TTM)630.60M
Net Income(TTM)-579.83M
Analysts85.19
Price Target85.47 (158.84%)
Short Float %9.47%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.03%
Min EPS beat(2)-43.75%
Max EPS beat(2)11.68%
EPS beat(4)2
Avg EPS beat(4)-8.27%
Min EPS beat(4)-43.75%
Max EPS beat(4)11.68%
EPS beat(8)5
Avg EPS beat(8)-2.83%
EPS beat(12)6
Avg EPS beat(12)-4.05%
EPS beat(16)6
Avg EPS beat(16)-13.56%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.94%
Max Revenue beat(2)1.02%
Revenue beat(4)2
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-5.94%
Max Revenue beat(4)4.02%
Revenue beat(8)5
Avg Revenue beat(8)1.05%
Revenue beat(12)6
Avg Revenue beat(12)-1.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.78%
PT rev (1m)-0.25%
PT rev (3m)-1.79%
EPS NQ rev (1m)-0.11%
EPS NQ rev (3m)4.47%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)-3.05%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)1.31%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)0.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.05 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 347.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.94
EYN/A
EPS(NY)-4.11
Fwd EYN/A
FCF(TTM)-4.84
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS6.54
BVpS0.1
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.71% | ||
| ROE | -6330.7% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.69% | ||
| FCFM | N/A |
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score2
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 83.39 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.7% | ||
| Cap/Sales | 3.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z | -4.21 |
F-Score2
WACC8.26%
ROIC/WACCN/A
Cap/Depr(3y)346.02%
Cap/Depr(5y)389.65%
Cap/Sales(3y)18.19%
Cap/Sales(5y)18.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
EPS Next Y18.8%
EPS Next 2Y16.29%
EPS Next 3Y23.42%
EPS Next 5Y25.18%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%
Revenue Next Year20.05%
Revenue Next 2Y21.83%
Revenue Next 3Y29.87%
Revenue Next 5Y32.44%
EBIT growth 1Y-1.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.09%
EBIT Next 3Y27.06%
EBIT Next 5YN/A
FCF growth 1Y15.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.39%
OCF growth 3YN/A
OCF growth 5YN/A
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What is the ChartMill fundamental rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to RARE.
What is the valuation status of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
ChartMill assigns a valuation rating of 1 / 10 to ULTRAGENYX PHARMACEUTICAL IN (RARE). This can be considered as Overvalued.
How profitable is ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
ULTRAGENYX PHARMACEUTICAL IN (RARE) has a profitability rating of 1 / 10.
What is the financial health of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?
The financial health rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 2 / 10.
Can you provide the dividend sustainability for RARE stock?
The dividend rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 0 / 10 and the dividend payout ratio is 0%.